An interventional study of Sevoflurane and Propofol in Anesthesia and Breast Cancer, sponsored by Moscow Clinical Scientific Center. Recruiting at 1 site in Russian Federation. Open to female participants aged 45 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-04-26.
Sponsored by Moscow Clinical Scientific Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Breast Neoplasms with a site in Russian Federation — 9 open to participants now, 10 under way, 1 of them phase 3. Breast Neoplasms · Russian Federation.
Among the 180 studies in Breast Neoplasms with a site in Russian Federation, this one is the 117th largest by planned enrollment of the 166 interventional ones that give a count, is one of 7 that started in 2022, is one of 7 with no phase, and was the 166th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 180 studies in Breast Neoplasms with a site in Russian Federation are open now. Recruiting first, the newest first:
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18–70 · Women only
N.N. Petrov National Medical Research Center of Oncology · Sites in Russian Federation
Ages 18+ · Women only
Moscow Clinical Scientific Center · Sites in Russian Federation
Ages 18–80
Branch Office of "Hadassah Medical Ltd" · Sites in Russian Federation
Ages 18+ · Women only
Population Health Research Institute · Sites in Russian Federation, Brazil, Canada
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 45 Years to 74 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 60 · Phase 3 94
First in 1996; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 334 across the 166 interventional studies, 300 across the 13 observational. Of the 154 that completed or were terminated, 121 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 180 have an industry lead sponsor. The 10 most frequent:
Moscow Clinical Scientific Center is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Moscow Clinical Scientific Center has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 180 studies in Breast Neoplasms with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Even decade ago it was believed that the choice method of anesthesia did not affect the course of the oncological process, but recent evidence has begun to emerge that inhalation anesthesia vs TIVA is associated with a higher number of adverse outcomes. Apparently, it makes sense to conduct mRCT in order to assess the effect of IA on immune system in patients operated on for breast cancer comprehensively. The results of that kind of RCT may finally give us an answer whether the choice of anesthesia affects the immune status of patients undergoing surgery for breast cancer. The evaluation of complications and long-term survival will allow to recommend to use or not to use IA for this type of surgery.
Objective: The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery
The power calculation for this study was based on an assessment of Neutrophil-lymphocyte ratio (NLR) in patients undergoing breast cancer resection with total intravenous and inhalation anesthesia in two studies:
The pooled mean NLR in the TIVA group is 3.25±1.34, in the inhalation anesthesia group: 4.03±1.78.
Difference in means (effect size): 0.78, for level α=0.05, power 1-β=80% and expected standard deviation of 1.5, 65 patients in each group should be recruited, taking into account a 10% margin (total number of patients: 130).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sevoflurane
Drug: Propofol
induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
propofol-based total intravenous anesthesia during breast cancer surgery
Neutrophil-lymphocyte ratio
Absolute number of neutrophils divided by the absolute number of lymphocytes
Time frame: 1 hour after surgery
Neutrophil-lymphocyte ratio
Absolute number of neutrophils divided by the absolute number of lymphocytes
Time frame: 24 hours after surgery
Matrix metallopeptidase 9
ng/mL
Time frame: 1 hour after surgery
Matrix metallopeptidase 9
ng/mL
Time frame: 24 hour after surgery
C-reactive protein
mg/L
Time frame: 1 hour after surgery
C-reactive protein
mg/L
Time frame: 24 hour after surgery
Natural killer cells of blood (CD3-CD16 +)
Absolute number (х 10\^9 /L)
Time frame: 1 hour after surgery
Natural killer cells of blood (CD3-CD16 +)
Absolute number (х 10\^9 /L)
Time frame: 24 hour after surgery
Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)
the ratio of T helper cells to cytotoxic T cells
Time frame: 1 hour after surgery
Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)
the ratio of T helper cells to cytotoxic T cells
Time frame: 24 hour after surgery
IL-6
pg/ml
Time frame: 1 hour after surgery
IL-6
pg/ml
Time frame: 24 hour after surgery
T cells of blood (CD3 +)
Absolute number (х 10 /L)
Time frame: 1 hour after surgery
T cells of blood (CD3 +)
Absolute number (х 10\^9 /L)
Time frame: 24 hours after surgery
T helpers of blood (CD3 + CD4 +)
Absolute number (х 10\^9 /L)
Time frame: 1 hour after surgery
T helpers of blood (CD3 + CD4 +)
Absolute number (х 10\^9 /L)
Time frame: 24 hours after surgery
Cytotoxic T cells of blood (CD3 + CD8 +)
Absolute number (х 10\^9 /L)
Time frame: 1 hour after surgery
Cytotoxic T cells of blood (CD3 + CD8 +)
Absolute number (х 10\^9 /L)
Time frame: 24 hours after surgery
B cells of blood (CD19 + CD3-)
Absolute number (х 10\^9 /L)
Time frame: 1 hour after surgery
B cells of blood (CD19 + CD3-)
Absolute number (х 10\^9 /L)
Time frame: 24 hour after surgery
T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood
percentage
Time frame: 1 hour after surgery
T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood
percentage
Time frame: 24 hours after surgery
Phagocytosis
percentage
Time frame: 1 hour after surgery
Phagocytosis
percentage
Time frame: 24 hours after surgery
IgA
g/L
Time frame: 1 hour after surgery
IgA
g/L
Time frame: 24 hours after surgery
IgM
g/L
Time frame: 1 hour after surgery
IgM
g/L
Time frame: 24 hours after surgery
IgG
g/L
Time frame: 1 hour after surgery
IgG
g/L
Time frame: 24 hours after surgery
Complement component C3
g/L
Time frame: 1 hour after surgery
Complement component C3
g/L
Time frame: 24 hours after surgery
Complement component C4
g/L
Time frame: 1 hour after surgery
Complement component C4
g/L
Time frame: 24 hours after surgery
Overall survival
percentage of survival patients
Time frame: 1 year
Overall survival
percentage of survival patients
Time frame: 3 year
Overall survival
percentage of survival patients
Time frame: 5 year
Disease-free survival
percentage of survival patients
Time frame: 1 year
Disease-free survival
percentage of survival patients
Time frame: 3 year
Disease-free survival
percentage of survival patients
Time frame: 5 year
Started Mar 2022 (actual). Primary completion is estimated for Jul 2023, 15 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 15 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevoflurane
Moscow Clinical Scientific Center